Loading stock data…
CORT
$77.49+4.16 (+5.67%)
After Hours$78.00+0.51 (+0.66%)· Last close Jun 9
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Corcept Therapeutics Incorporated in the Healthcare sector is trading at $77.49. Wall Street consensus targets $88.00 (5 analysts), implying a +13.6% move over the next 12 months. The stock is currently 15% below its 52-week high of $91.00, remaining 30.1% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$77.49
Potential Downside
0%
Whystock Fair Value$77.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$88.00+13.6%
Range$50.00 – $135.00
Fundamentals
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.42%
Volume
Today's trading volume
1.00M
Recent News
ATRenew And Two Insider-Favored Growth Stocks To Watch
Over the last 7 days, the United States market has dropped 2.7%, yet it has shown resilience with a 23% rise over the past year and expectations for earnings to grow by 17% annually in the coming years. In this context, growth companies with high insider ownership, such as ATRenew and two others we'll explore, can be particularly appealing as they often indicate strong internal confidence in their long-term potential.
3 Growth Stocks With High Insider Ownership And 29% Revenue Growth
Over the last 7 days, the United States market has experienced a 2.7% drop, yet it has risen by 23% over the past year with earnings expected to grow by 17% annually. In this context, growth stocks with high insider ownership can offer unique insights into potential opportunities as insiders may have confidence in their company's future prospects and are often aligned with shareholder interests.
3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth
Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Insider Favorites High Growth Companies June 2026
Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing as these firms often demonstrate strong potential and a vested interest from those who know them best.